Japan Drug Makers Move To Biotech Generics Under New Rules
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers seek to take advantage of new government drug guidelines to develop and market their own generic versions of drugs based on biotechnology. Such drugs often are more expensive to produce than conventional drugs because of the genetic engineering and other techniques involved. Aska Pharmaceutical, which specializes in gynecological medicines, and JCR Pharmaceuticals, which concentrates on cell cultivation, plan a joint trial of an infertility generic, possibly next year. Biotech generics are expected to cost about 30 percent less than innovative ones as a result of the new guidelines. (Click here for more - a subscription may be required
|
Japanese drug makers seek to take advantage of new government drug guidelines to develop and market their own generic versions of drugs based on biotechnology. Such drugs often are more expensive to produce than conventional drugs because of the genetic engineering and other techniques involved. Aska Pharmaceutical, which specializes in gynecological medicines, and JCR Pharmaceuticals, which concentrates on cell cultivation, plan a joint trial of an infertility generic, possibly next year. Biotech generics are expected to cost about 30 percent less than innovative ones as a result of the new guidelines. (Click here for more - a subscription may be required) "Japan Drug Makers Developing Biotech Generics" - Nikkei (Japan) (6/5/09) |